Skip to NavigationSkip to content

Johnson & Johnson

Congressman says FDA should scrutinise J&J's manufacturing partners

The latest flurry of recalls from Johnson & Johnson has prompted additional calls for a wide-ranging investigation of the company's manufacturing network by US regulators.

Congressman Darrell Issa wants the FDA to probe not only J&J's own facilities but also its relationship with contract manufacturers, following last week's recall of 13 million Rolaids packs due to contamination with wood or metal particles.

Race on to find new Johnson & Johnson leader

Johnson & Johnson is promoting two of its most senior executives as it prepares to replace William Weldon, its current chairman and chief executive.

Sheri McCoy, who has been running J&J’s pharma group, and Alex Gorsky, previously chief of the company’s medical-devices and diagnostics division, have both been promoted to vice chairmen in the expanded ‘Office of the Chairman’.

The promotions are an explicit part of the company’s succession plan, with its board eventually choosing between the two candidates for the top job.

Millions more OTC products recalled by J&J

Johnson & Johnson has been forced to announce yet another recall of over-the-counter medicines manufactured at its Fort Washington facility in Pennsylvania, USA, this time citing manufacturing "insufficiencies".

The voluntary recall involves almost five million packs of McNeil Consumer healthcare brand products.

J&J and Takeda issue recall for cancer drug Velcade

Johnson & Johnson has been affected by another product recall, on this occasion concerning the cancer drug Velcade (bortezomib) sold by its Janssen-Cilag unit alongside Takeda Pharmaceuticals.

Given the problems J&J has had of late with its own manufacturing network, it will be something of a relief for the company that this time it was not responsible for manufacturing the defective product.

Pharma engages HTA bodies in early-stage drug discussions

AstraZeneca cancer research
Cancer research at AstraZeneca - drug development in the therapy area will be discussed as part of the pilot

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA).

AstraZeneca, GlaxoSmithKline and Johnson & Johnson are funding and taking part in the new initiative, which aims to move closer to a common definition of what evidence is needed to demonstrate safety, efficacy and ‘value’.

Johnson & Johnson recalls more Tylenol

Johnson & Johnson Tylenol

Johnson & Johnson's McNeil Consumer Healthcare unit has announced yet another recall affecting its Tylenol painkiller range.

The latest recall - the twelfth announced by the company in the last 12 months - is a much more limited affair as it affects only around 128,000 bottles of Tylenol 8-Hour caplets, a mere handful in the context of the millions of products already withdrawn from sale.

J&J chief admits mistakes at Congressional hearing

Johnson & Johnson chief executive William Weldon admitted yesterday that his company had failed to maintain quality standards and mishandled recalls at its subsidiary McNeil Consumer Health.

Speaking in front of a congressional committee convened to investigate the circumstances behind the recall of an estimated 135 million over-the-counter medications, Weldon said he accepted full responsibility for the quality lapses, whilst announcing a $100 million investment programme to help set the company's manufacturing operations to rights.

J&J's Weldon will appear at next congressional hearing

Johnson & Johnson chief executive William Weldon will appear in person at the next congressional hearing on the company’s wide-ranging recall of consumer healthcare products, according to the company.

The meeting on 30 September is focusing increasingly on what has been described as a 'phantom' recall of the company's Motrin (ibuprofen) product in 2009, in which it is alleged that contractors hired by J&J systematically bought back supplies of the painkiller in order to avoid a public recall notice.

J&J to acquire Crucell for $2.3 billion

Crucell's Leiden headquarters
Crucell's headquarters in Leiden, Holland

Johnson & Johnson is set to buy out Crucell for around $2.3 billion (1.75 bn euros) expanding its presence in the vaccines market.

The US giant already holds a stake of just under 18% in the company, but is now in talks with the Dutch vaccines company to buy its remaining shares.

The deal represents a purchase price of euro 24.75 per share, and the public offer would be an all cash transaction.

J&J and Merck heading for showdown over drug rights

Johnson & Johnson’s disagreement with Merck over rights to two arthritis drugs is set to come to a head in the next few weeks.

Revenues from sales of Remicade (infliximab) and Simponi (golimumab) could be due to Johnson & Johnson if arbitration, expected to start this month, goes its way.

It is a potentially very expensive situation for Merck, as it could result in the full marketing rights of the products in non-US markets reverting to Johnson & Johnson.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches